Analytical Data
-
Gene name
EFHD1
- Application
-
Alternative Names
4931430I01Rik; AI452351; DKFZp781H0842.; EF hand domain containing 1; EF hand domain family; member D1; EF-hand domain-containing protein 1; EF-hand domain-containing protein D1; EFHD1; EFHD1_HUMAN; FLJ13612
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BUP0
-
Expression Region
1-239aa
-
AA Sequence
MASEELACKLERRLRREEAEESGPQLAPLGAPAPEPKPEPEPPARAPTASADAELSAQLSRRLDINEGAARPRRCRVFNPYTEFPEFSRRLIKDLESMFKLYDAGRDGFIDLMELKLMMEKLGAPQTHLGLKSMIKEVDEDFDGKLSFREFLLIFHKAAAGELQEDSGLMALAKLSEIDVALEGVRGAKNFFEAKVQALSSASKFEAELKAEQDERKREEEERRLRQAAFQKLKANFNT
-
Molecular Weight
53.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EFHD1, or EF-hand domain-containing protein 1, has gained attention in recent years for its potential roles in cellular processes, particularly in calcium signaling and its implications in neurobiology and muscle function. Research has shown that EFHD1 is involved in modulating calcium-dependent signaling pathways, which are crucial for a variety of physiological processes including muscle contraction, neurotransmitter release, and cell survival. Studies indicate that dysregulation of EFHD1 may contribute to various pathologies, including neurodegenerative diseases, where calcium overload is a common feature. Additionally, EFHD1 has been implicated in key interactions with other proteins and cellular components, suggesting a multi-faceted role in cellular homeostasis. Given the increasing evidence connecting EFHD1 to critical biological functions, the characterization of its recombinant protein holds promise for understanding its precise mechanisms of action. By producing and studying EFHD1 recombinantly, researchers aim to uncover its structural and functional characteristics, enabling further exploration of its potential as a therapeutic target. Overall, the study of EFHD1 not only enhances our understanding of calcium signaling but also opens avenues for novel interventions in conditions where these pathways are disrupted.
